RLS-0071 — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-12 (month) in 4mo
ESTIMATED |
READOUT
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary
Phase 2 · Hypoxic-Ischemic Encephalopathy |
ReAlta Life Sciences, Inc. | RLS-0071 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-12 (month) in 4mo
ESTIMATED |
READOUT
Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalize
Phase 2 · Steroid Refractory GVHD |
ReAlta Life Sciences, Inc. | RLS-0071 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|